C22.0
Conditions
Interventions
Group 1: Patients with advanced HCC and immunotherapy-based first-line therapy
Patients are included at the timepoint of therapy initiation. Epidemilogical-, clinical- as well as laboratory parameter
Sponsors
Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with advanced HCC (Barcelona Clinic Liver Cancer (BCLC) classification B/C) and planned first-line systemic treatment using immunotherapy (combination therapy) in accordance with the decision of the local tumor conference The HCC must have arisen from the following etiologies: MASLD, alcohol-induced liver cirrhosis, viral-induced liver cirrhosis
Exclusion criteria
Exclusion criteria: Previous systemic therapy or treatment with immune checkpoint inhibitors (only for HCC) HCC due to the following liver diseases: cryptogenic liver cirrhosis, autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), haemochromatosis, Wilson's disease, alpha-1-antitrypsin deficiency Combined hepatocellular-cholangiocellular carcinoma, fibrolamellar HCC No written consent possible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (defined as the time-interval between study inclusion at the start of treatment and the patient's death) Survival data is collected either by notification of the relatives or by telephone contact | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate (defined as best tumor response under therapy) The data is recorded on the basis of the quarterly imaging diagnostics performed as part of the clinical routine | — |
Countries
Germany
Contacts
Public ContactCatherine Leyh
Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie
Outcome results
None listed